# OnCo record eu-hta-regulation (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/eu-hta-regulation/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "eu-hta-regulation" ;
  schema:name "EU HTA Regulation (EU) 2021/2282: joint clinical assessments"@en ;
  schema:alternateName "HTA Regulation"@en, "HTAR"@en, "Regulation 2021/2282"@en, "joint clinical assessment"@en, "joint clinical assessments"@en, "JCA"@en, "JCAs"@en, "joint scientific consultation"@en, "Member State Coordination Group on HTA"@en, "HTACG"@en ;
  schema:description "From January 2025 every new cancer medicine in the EU gets one shared assessment of how well it works compared with existing treatments, done jointly by member states, so that each country's payer no longer repeats the clinical review, though each still decides on price."@en ;
  schema:url <https://onco.cc/terms/eu-hta-regulation/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://eur-lex.europa.eu/eli/reg/2021/2282/oj>, <https://health.ec.europa.eu/health-technology-assessment_en> ;
  onco:tag "law", "eu" ;
  onco:related <https://onco.cc/terms/hta/>, <https://onco.cc/terms/icer-value-assessment/>, <https://onco.cc/terms/nice-methods/>, <https://onco.cc/terms/amnog/>, <https://onco.cc/terms/eu-regulation-726-2004/>, <https://onco.cc/terms/eu-pharma-package/>, <https://onco.cc/terms/european-health-data-space/>, <https://onco.cc/terms/inflation-reduction-act/>, <https://onco.cc/terms/qol-pro/> ;
  onco:institutions <https://onco.cc/institutions/ema/>, <https://onco.cc/institutions/g-ba-iqwig/>, <https://onco.cc/institutions/has-france/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-regulatory-fragmentation/>, <https://onco.cc/bottlenecks/b-global-access/> .